Targeting HER2-positive breast cancer: advances and future directions. [Review] (Record no. 10972)

MARC details
000 -LEADER
fixed length control field 02117nam a22003737a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 221213s20222022 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1474-1776
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 10.1038/s41573-022-00579-0 [doi]
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 10.1038/s41573-022-00579-0 [pii]
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code PMC9640784 [pmc]
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 36344672
245 ## - TITLE STATEMENT
Title Targeting HER2-positive breast cancer: advances and future directions. [Review]
251 ## - Source
Source Nature Reviews. Drug Discovery. 2022 Nov 07
252 ## - Abbreviated Source
Abbreviated source Nat Rev Drug Discov. 2022 Nov 07
253 ## - Journal Name
Journal name Nature reviews. Drug discovery
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2022
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2023
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Publication date 2022 Nov 07
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Publication status aheadofprint
266 ## - Date added to catalog
Date added to catalog 2022-12-13
520 ## - SUMMARY, ETC.
Abstract The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug - the monoclonal antibody trastuzumab - almost 25 years ago. Since then, progress has been swift and the impressive clinical activity across multiple trials with monoclonal antibodies, tyrosine kinase inhibitors and antibody-drug conjugates that target HER2 has spawned extensive efforts to develop newer platforms and more targeted therapies. This Review discusses the current standards of care for HER2-positive breast cancer, mechanisms of resistance to HER2-targeted therapy and new therapeutic approaches and agents, including strategies to harness the immune system. Copyright © 2022. Springer Nature Limited.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element IN PROCESS -- NOT YET INDEXED
656 ## - INDEX TERM--OCCUPATION
Department Associate Dean for Research Development
656 ## - INDEX TERM--OCCUPATION
Department MedStar Health
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
657 ## - INDEX TERM--FUNCTION
Medline publication type Review
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Swain, Sandra M
Institution Code MSH
790 ## - Authors
All authors Hamilton E, Shastry M, Swain SM
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.1038/s41573-022-00579-0">https://dx.doi.org/10.1038/s41573-022-00579-0</a>
Public note https://dx.doi.org/10.1038/s41573-022-00579-0
858 ## - ORCID
ORCID text Swain, Sandra M
Orcid <a href="http://orcid.org/0000-0002-1320-3830">http://orcid.org/0000-0002-1320-3830</a>
Name http://orcid.org/0000-0002-1320-3830
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 12/13/2022   36344672 36344672 12/13/2022 12/13/2022 Journal Article

Powered by Koha